Chadi A Calarge1, James A Mills2, Kathleen F Janz3, Trudy L Burns4, William H Coryell2, Babette S Zemel5. 1. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas; chadi.calarge@bcm.edu. 2. Department of Psychiatry. 3. Health and Human Physiology, College of Liberal Arts and Sciences, and. 4. College of Public Health, The University of Iowa, Iowa City, Iowa; and. 5. Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
OBJECTIVES: To examine the independent contribution of major depressive disorder (MDD), generalized anxiety disorder (GAD), and selective serotonin reuptake inhibitors (SSRIs) to changes in body composition in older adolescents. METHODS: Medically healthy 15- to 20-year-olds who were unmedicated or within 1 month of starting an SSRI were prospectively followed. Psychiatric functioning and medication treatment were assessed monthly. Body Mass Index (BMI) was measured every 4 months. Every 8 months, a whole-body dual-energy radiograph absorptiometry scan was obtained to determine lean BMI, fat mass index, and visceral fat mass. Linear mixed effects regression analysis examined associations between MDD, GAD, and SSRI use variables and body composition measures. RESULTS: Over 1.51 ± 0.76 years of follow-up, 264 participants contributed 805 observations. After adjusting for age, sex, physical activity, dietary intake, and time in the study, MDD severity was inversely associated, prospectively, with BMI, fat mass index, and lean BMI z scores, whereas cumulative SSRI treatment duration and dose were positively associated with these outcomes. GAD severity and diagnosis were not significantly associated with any body composition outcome. Moreover, citalopram and escitalopram were most strongly associated with the increase in all body composition measures, including visceral fat mass, whereas the associations with fluoxetine were somewhat weaker. Sertraline was not different from no SSRI treatment. CONCLUSIONS: Depression severity was associated with a decrease in measures of body composition in older adolescents over a mean of 1.5 years, whereas SSRI treatment was positively associated with these outcomes, with differential effects across treatment groups.
OBJECTIVES: To examine the independent contribution of major depressive disorder (MDD), generalized anxiety disorder (GAD), and selective serotonin reuptake inhibitors (SSRIs) to changes in body composition in older adolescents. METHODS: Medically healthy 15- to 20-year-olds who were unmedicated or within 1 month of starting an SSRI were prospectively followed. Psychiatric functioning and medication treatment were assessed monthly. Body Mass Index (BMI) was measured every 4 months. Every 8 months, a whole-body dual-energy radiograph absorptiometry scan was obtained to determine lean BMI, fat mass index, and visceral fat mass. Linear mixed effects regression analysis examined associations between MDD, GAD, and SSRI use variables and body composition measures. RESULTS: Over 1.51 ± 0.76 years of follow-up, 264 participants contributed 805 observations. After adjusting for age, sex, physical activity, dietary intake, and time in the study, MDD severity was inversely associated, prospectively, with BMI, fat mass index, and lean BMI z scores, whereas cumulative SSRI treatment duration and dose were positively associated with these outcomes. GAD severity and diagnosis were not significantly associated with any body composition outcome. Moreover, citalopram and escitalopram were most strongly associated with the increase in all body composition measures, including visceral fat mass, whereas the associations with fluoxetine were somewhat weaker. Sertraline was not different from no SSRI treatment. CONCLUSIONS:Depression severity was associated with a decrease in measures of body composition in older adolescents over a mean of 1.5 years, whereas SSRI treatment was positively associated with these outcomes, with differential effects across treatment groups.
Authors: Arianne K B van Reedt Dortland; Sophie A Vreeburg; Erik J Giltay; Carmilla M M Licht; Nicole Vogelzangs; Tineke van Veen; Eco J C de Geus; Brenda W J H Penninx; Frans G Zitman Journal: Psychoneuroendocrinology Date: 2012-06-18 Impact factor: 4.905
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: Laura P Richardson; Robert Davis; Richie Poulton; Elizabeth McCauley; Terrie E Moffitt; Avshalom Caspi; Frederick Connell Journal: Arch Pediatr Adolesc Med Date: 2003-08
Authors: Chadi A Calarge; Brandon D Butcher; Trudy L Burns; William H Coryell; Janet A Schlechte; Babette S Zemel Journal: J Bone Miner Res Date: 2014-10 Impact factor: 6.741
Authors: William H Coryell; Brandon D Butcher; Trudy L Burns; Lilian N Dindo; Janet A Schlechte; Chadi A Calarge Journal: J Clin Psychiatry Date: 2016-01 Impact factor: 4.384
Authors: Chadi A Calarge; James A Mills; Lefkothea Karaviti; Antonio L Teixeira; Babette S Zemel; Jose M Garcia Journal: J Pediatr Date: 2018-06-27 Impact factor: 4.406
Authors: Chadi A Calarge; James A Mills; Kathleen F Janz; Trudy L Burns; Janet A Schlechte; William H Coryell; Babette S Zemel Journal: J Bone Miner Res Date: 2017-09-22 Impact factor: 6.741
Authors: Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey Journal: Front Pharmacol Date: 2019-02-19 Impact factor: 5.810
Authors: Jeffrey R Strawn; Ethan A Poweleit; Jeffrey A Mills; Heidi K Schroeder; Zoe A Neptune; Ashley M Specht; Jenni E Farrow; Xue Zhang; Lisa J Martin; Laura B Ramsey Journal: J Pers Med Date: 2021-11-12